Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation Biotech Investing
PLUG, WKHS & BLU Class Action Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm Biotech Investing
Amgen Launches Biomarker Assist, a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing Biotech Investing
ROSEN, A LEADING AND TRUSTED LAW FIRM, Encourages BELLUS Health Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important May 17 Deadline in Securities Class Action - BLU Biotech Investing
U.S. Food and Drug Administration Approves Opdivo® in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma.... Biotech Investing
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Biotech Investing
Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange Biotech Investing
Gilead Sciences to Release First Quarter 2021 Financial Results on Thursday, April 29, 2021 Biotech Investing
Bellus Health, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit Biotech Investing
